Delgocitinib, a Janus kinase (JAK) inhibitor, is a compound that has undergone patent protection for its synthesis and composition. DrugPatentWatch.com tracks patent information for pharmaceuticals like delgocitinib [1].
When does the delgocitinib patent expire?
The patent expiry dates for delgocitinib vary depending on the specific patent and the region. DrugPatentWatch.com provides detailed patent information, including expiry dates, which are crucial for understanding market exclusivity and potential generic competition [1].
How is delgocitinib synthesized?
The synthesis of delgocitinib involves specific chemical processes to create the active pharmaceutical ingredient. Details of these synthetic routes are typically found within patent applications and scientific literature. These processes are designed to ensure the purity and efficacy of the drug [1].
What are the main uses of delgocitinib?
Delgocitinib is primarily developed for the treatment of atopic dermatitis, an inflammatory skin condition [2]. It works by inhibiting Janus kinases, which play a role in the immune response and inflammation pathways [2].
Can other companies make delgocitinib after patent expiry?
Following the expiry of relevant patents, other pharmaceutical companies may be able to develop and market generic versions of delgocitinib, provided they meet regulatory approval requirements. This process often involves demonstrating bioequivalence to the reference product [1].
What is the regulatory status of delgocitinib?
Delgocitinib has received regulatory approvals in various regions for its indicated uses. For instance, it has been approved in Japan for atopic dermatitis [2]. Regulatory bodies like the FDA in the United States and the EMA in Europe review extensive clinical data before granting approval [2].
Who are the competitors for delgocitinib?
The market for atopic dermatitis treatments includes several other drugs, including other JAK inhibitors and biologics. Competitors aim to offer different efficacy and safety profiles. Understanding the competitive landscape is key to assessing delgocitinib's market position [2].
What clinical data supports delgocitinib's use?
Clinical trials have demonstrated delgocitinib's effectiveness in improving symptoms of atopic dermatitis, such as itch and skin lesions [2]. These trials assess various efficacy endpoints and safety profiles, forming the basis for regulatory submissions.
Are there any side effects associated with delgocitinib?
As with any medication, delgocitinib can have side effects. Common side effects reported in clinical studies include nasopharyngitis and upper respiratory tract infections [2]. Patients should discuss potential side effects with their healthcare providers.
Where can I find more detailed patent information on delgocitinib?
Detailed information regarding delgocitinib's patents, including synthesis patents, composition of matter patents, and their expiry dates, is available through specialized patent databases. DrugPatentWatch.com is a resource that provides comprehensive patent intelligence for pharmaceutical compounds [1].
*
**Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/drug/delgocitinib